Preparation of gelatin/epigallocatechin gallate self-assembly nanoparticles for transdermal drug delivery

Functional nano-systems for transdermal drug delivery and skin therapy

“…In this study, cell viability assays indicated that 10 μg mL −1 concentrations of EGCG or GE were non-toxic to human dermal fibroblast (WS1) cells. 241 Moreover, Au-NPs with 5 nm at a concentration up to 200 mM were shown to be safe to keratinocytes, since materials with cell viability more than 80% are often considered as biocompatible. 242 While cell-based in vitro research is important to determining the toxicity toward specific cells or tissues, in vivo experiments are essential to test their systemic toxicity for the organs and the whole body.…”

Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis

“…Since catechins such as EGCG have been highlighted for their outstanding pharmacological activity on the skin, including the wound-healing effect, antiaging, antiacne, antipsoriatic properties, and, more importantly, the effect on AD, several strategies have been attempted for their nanoencapsulation [ 91 ]. The work of Drew et al [ 14 ] showed that gelatin/EGCG nanoparticles (GE NPs) were efficient in reducing IL-6 and IL-8 inflammatory factors, using an in vitro model of lipopolysaccharide (LPS)-inflamed WS1 dermal fibroblasts, at non-toxic concentrations lower than 10 µg/mL. Furthermore, in vivo assays conducted on nude mouse skin (BALB/cAnN.Cg-Foxn1nu/CrlNarl mice) also showed that GE NPs present skin absorbance but do not cause adverse effects.…”

“…Furthermore, in vivo assays conducted on nude mouse skin (BALB/cAnN.Cg-Foxn1nu/CrlNarl mice) also showed that GE NPs present skin absorbance but do not cause adverse effects. In this study, the formulated GE NPs were prepared following a self-assembly mechanism, and NPs showed an average size of 112.5 ± 19.09 nm, a positive ZP 23.2 ± 0.5 mV, and a PDI of 0.3 ± 0.05 [ 14 ].…”

“…To overcome some transdermal delivery problems, augment drug-to-site targeting, solve problems related to active compounds’ solubility, and increase efficacy of such natural ingredients in AD treatment, some nanotechnology-based solutions have been developed in recent years. As successful examples that are herein reviewed, investigators designed quercetin nanostructured lipid carriers [ 12 ], solid lipid nanoparticles loaded with capsaicin, curcurmin, and resveratrol [ 13 ], nanoparticles of epigallocatechin-3-gallate [ 14 , 15 ], transfersomes loaded with glycyrrhizic acid [ 16 ], innovative phytosomes with Centella asiatica (L.) Urban extracts [ 17 ], nanocapsule-based films of pomegranate seed oil [ 18 ], and ethosome-based cream of tea tree oil [ 19 ], and several other formulations presented throughout this paper.…”

Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis

“…To overcome some transdermal delivery problems, augment drug-to-site targeting, solve problems related to active compounds' solubility, and increase efficacy of such natural ingredients in AD treatment, some nanotechnology-based solutions have been developed in recent years. As successful examples that are herein reviewed, investigators designed quercetin nanostructured lipid carriers [12], solid lipid nanoparticles loaded with capsaicin, curcurmin, and resveratrol [13], nanoparticles of epigallocatechin-3-gallate [14,15], transfersomes loaded with glycyrrhizic acid [16], innovative phytosomes with Centella asiatica (L.) Urban extracts [17], nanocapsule-based films of pomegranate seed oil [18], and ethosome-based cream of tea tree oil [19], and several other formulations presented throughout this paper.…”